title: Loss of prostaglandin E2-induced extra cortical bone after its withdrawal in rats.
abstract: The object of this study was to determine the fate of PGE2-induced new cortical bone mass after withdrawal of PGE2 administration. Seven-month-old male Sprague-Dawley rats were given subcutaneous injections of 1, 3 and 6 mg PGE2/kg/day for 60 days and then withdrawn for 60 and 120 days (on/off treatment). Histomorphometric analyses were performed on double-fluorescent-labeled undecalcified tibial shaft sections (proximal to the tibiofibular junction). In a previous report we showed that after 60, 120 and 180 days of daily PGE2 (on)treatment, a new steady state was achieved marked by increased total bone area (+16%, +25% and +34% with 1, 3 and 6 mg PGE2/kg/day) when compared to age-matched controls. The continuous PGE2 treatment stimulated periosteal and endocortical lamellar bone formation, activated endocortical woven trabecular bone formation and intracortical bone resorption. These responses increased cortical bone mass since the bone formation exceeded bone resorption. The current study showed that after withdrawal of PGE2 for 60 and 120 days, the extra endocortical bone, which was induced by the first 60-days treatment, was resorbed, but the new subperiosteal bone persisted resulting in a tibial shaft with larger cross sectional and marrow areas. Despite that, there was still the same amount of bone mass in these shafts as in age-related controls. A new steady state was achieved after 60 days of withdrawal, in which the bone mass and bone formation activity approximated that of age-related controls. It was concluded that maintaining the extra PGE2-induced cortical bone mass depends on continuous daily administration of PGE2.
authors.affiliation: Division of Radiobiology, University of Utah School of Medicine, Salt Lake City 84112.
authors.forename: W S
authors.initials: WS
authors.lastname: Jee
authors.forename: H Z
authors.initials: HZ
authors.lastname: Ke
authors.forename: X J
authors.initials: XJ
authors.lastname: Li
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects*; D001862:Bone Resorption / Q000209:etiology*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D015232:Dinoprostone / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008856:Microscopy, Fluorescence; D051381:Rats; D011919:Rats, Inbred Strains; D013977:Tibia
chemical_list: D015232:Dinoprostone